We are live on !
Find out more
Kinnevik Portfolio holdings
AUM
$65.6M
Turnover
0%
1-Year Est. Return
25.95%
This Fund
S&P 500
This Quarter Est. Return
-24.77%
1 Year Est. Return
-25.95%
3 Year Est. Return
-51.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$89.3M
AUM Growth
-$14.5M
(-14%)
Cap. Flow
+$13.1M
Cap. Flow % of AUM
Cap. Flow %
14.65%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
1
Reduced
–
Closed
–
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Recursion Pharmaceuticals
RXRX
|
+$13.1M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
KAM
EVP
A
Kinnevik's Q2 2024 Portfolio in Review
As of Q2 2024, Kinnevik held 1 position worth $89.3M, down 14% from $104M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Kinnevik deployed $13.1M of net new capital in Q2 2024, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Kinnevik added most to Recursion Pharmaceuticals in Q2 2024, an estimated $13.1M increase.
- Kinnevik's ten largest holdings make up 100% of its $89.3M portfolio in Q2 2024.
- Kinnevik opened 0 new positions and closed 0 in Q2 2024.
- Kinnevik's portfolio value fell 14% quarter-over-quarter to $89.3M.
Based on Kinnevik's 13F filing for Q2 2024, filed 8 Jul 2024.